text:  The BEMED study BMJ 2016 352 DOI 10 1136 was designed as multi centric double blind plaebo controlled study in patients with Menières disease It should compare a low level 2 24 mg d vs high level 3 48 mg d betahstine intake vs placebo The primary endpoint was the number of vertigo attacks lasting longer than 20 min as documented in a patients diary The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo Therefore the BEMED study should be critically discussed in the present paper 